Key Growth Opportunities in the Vaccine Industry
Building Capabilities for the Development of Nucleic Acid-based Vaccines
DNA/mRNA vaccines are expected to emerge
as promising tools for chronic diseases as the
integration of advanced platforms and algorithms
reduced the development timeline for these
vaccines during the pandemic.
The growing focus on personalized nucleic
acid-based vaccine programs for cancer reflects
the potential of mRNA vaccines in chronic
disease areas such as cancer and HIV.
Exploring New Disease Areas to Mitigate the Growing Need for Immunizations
Untouched disease areas are being explored by vaccine developers to pioneer breakthroughs. Companies should reform and utilize their technologically advanced vaccine platforms and models designed for COVID-19 vaccine development to initiate R&D in potential areas such as diabetes, asthma, and cancer.
Bioengineering techniques should be incorporated to
increase the production of specific proteins required in
the vaccine manufacturing process, which will save
production time.
Tech Transfer in Emerging Economies to Boost Vaccine Production Efficiency and Pace
Identifying the unmet needs of vaccines and disease outbreaks in developing countries can be an initial step for vaccine developers to design expansion strategies and tech transfers in potential regions.
The pandemic accelerated the requirement for vaccines in
Asia and Africa, where tech transfers have played a critical role in catering to the rising demand. Vaccine manufacturers should shift their non-COVID-19 vaccine manufacturing processes to other production sites to boost capability building in
developing nations.
Created with Sketch.